TABLE 1

Evaluation of adverse reactions and CSF clinical signs after an immunization-and-challenge trial in pigs and of visible pathological lesions after postmortem examinationa

GroupPigPostimmunizationPostchallengePostmortem
LRFDFIFDFIDepLPIHSKPNINT
A (E2, 100 μg)40N0V
70N0N
100N0N
180N0N
190N0N
220N0N
B (E2, 50 μg)30N0N
80N0V+
200V0N
230N0N+
280N0N
290N0N
C (E2, 25 μg)110N0N+
120N0V
150N0N
240N0N
260N0N
300N0V
D (purified E2, 25 μg)10N0N
90N0N
130N0N+
210N0N
250N0V
270V0N
E (placebo)20N8L+++++
50N10L++++
60N8L++++++
140N10V++
160V10L++++++
170N8L+++++
  • a Pigs were immunized with different doses of E2-CSFV formulated within the whey of adenovirally transduced goats. Groups A to C received vaccine preparations containing 100, 50, and 25 μg of E2, respectively, in an oil-based adjuvant. Group D was immunized with 25 μg of E2 purified from the milk, while group E was injected with adjuvanted goat whey without E2 antigen. Two weeks after challenge, all animals were euthanized for necropsy and tissue analysis. Abbreviations: LR, local reactogenicity; FI, food intake (N, normal; V, variable; L, low); Dep, depression; PLL, perivascular lymphocyte infiltration in the brain; HS, hemorrhage in spleen; KP, kidney petechiae; NI, necrotic ileum; NT, necrotic tonsil; FD, number of days with fever (rectal temperature above 40°C).